RT Journal Article
SR Electronic
T1 Inactive disease in lupus patients is linked to autoantibodies to type-I interferons that normalize blood IFNα and B cell subsets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.07.21255049
DO 10.1101/2021.04.07.21255049
A1 Madhvi Menon
A1 Hannah F. Bradford
A1 Liis Haljasmagi
A1 Martti Vanker
A1 Pärt Peterson
A1 Chris Wincup
A1 Rym Abida
A1 Raquel Fernandez Gonzalez
A1 Vincent Bondet
A1 Darragh Duffy
A1 David A. Isenberg
A1 Kai Kisand
A1 Claudia Mauri
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.07.21255049.abstract
AB Systemic Lupus Erythematosus (SLE) is characterized by a prominent increase in expression of type-I interferon (IFN)-regulated genes in 50-75% of patients. Here we investigate the presence of autoantibodies (auto-Abs) against type I IFN in SLE patients and their possible role in controlling disease severity. We report that out of 491 SLE patients, 66 had detectable anti-IFNα-auto-Abs. The presence of neutralizing anti-IFNα-auto-Abs correlates with lower levels of circulating IFNα protein, inhibition of IFN down-stream signalling molecules and gene signatures and with an inactive global disease score. Previously reported B cell frequency abnormalities, found to be involved in SLE pathogenesis, including increased levels of immature, double negative and plasmablast B cell populations were partially normalized in patients with neutralising anti-IFNα-auto-Abs compared to other patient groups. We also show that sera from SLE patients with neutralising anti-IFNα-auto-Abs biases in vitro B cell differentiation towards classical memory phenotype, while sera from patients without anti-IFNα-Abs drives plasmablasts differentiation. Our findings support a role for neutralising anti-IFNα-auto-Abs in controlling SLE pathogenesis and highlight their potential efficacy as novel therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is funded by Versus Arthritis UK program grant (21140) and Research Award (21786) to C.M., by the European Regional Development Fund (Project No 2014- 2020.4.01.15-0012 and the Centre of Excellence in Genomics (EXCEGEN) framework) (LH, PP, KK), the Estonian Research Council grants PRG1117 (KK) and PRG377 (PP). H.F.B. is funded by a UCB BIOPHARMA SPRL/BBSRC PhD Studentship (BB/P504725/1). We thank Immunoqure for provision of mAbs for the pan-IFNa assay under an MTA to D.D. D.D. acknowledges support from the ANR (CE17001002). We thank Drs. Diego Catalan and Christopher Piper for critically reviewing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCLH Health Service ethical committee, REC reference no. 14/SC/1200All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data sets were generated or analysed during the current study.